WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

WilmerHale Reps Vtesse Inc. in Acquisition by Sucampo

Firm News

Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, and Vtesse Inc., a privately held rare disease company, announced that Sucampo has acquired Vtesse for upfront consideration of $200 million. Sucampo funded the acquisition through the issuance of 2,782,678 shares of Sucampo Class A common stock and $170 million of cash on hand; no external financing was utilized.

Steven Singer and Gary Schall led WilmerHale's representation of Vtesse in this transaction, with a team that included Steven Barrett, William Caporizzo, Jeffrey Hermanson, Scott Kilgore, David Sluis, Libby Ragan, Ben Kelsey and Alan Wilson.

View Vtesse's press release for details.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.